Business
Preclinical Data for SRA737 Presented at AACR 2019
Preclinical Data for SRA737 Presented at AACR 2019.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 7623U Sareum Holdings PLC 02 April 2019 \n\n\n\n\n(AIM: SAR)\n\n\n2 April 2019\n\n\n\n \nSareum Holdings plc\n(\"Sareum\" or \"the Company\")\n \nSareum notes new preclinical data demonstrating durable tumour regression with SRA737 plus low dose chemotherapy combined with anti-PD-L1 immunotherapy in small cell lung cancer model presented at AACR 2019 \nSareum Holdings plc (AIM: SAR), the specialist small molecule drug development business, notes that Sierra Oncology (\"Sierra\"), the licence holder advancing clinical cancer candidate SRA737, announced late yesterday that new preclinical data for SRA737, its Chk1 inhibitor, plus low dose gemcitabine (LDG), in combination with anti-PD-L1 immunotherapy, has been reported in a late-breaking oral presentation at the American Association of Cancer Research (AACR) Annual Meeting 2019, being held in Atlanta, GA, USA from 29 March to 3 April 2019.\n \nIn the study, SRA737+LDG demonstrated significant anti-tumour activity when combined with anti-PD-L1 immunotherapy in a mouse model of small cell lung cancer (SCLC), resulting in durable tumour regressions. 10/10 examples showed tumour regression at the end of the 21-day treatment period and 8/10 showed sustained complete response after a further 39 days without further treatment. \n \nThese findings suggest that the combination of anti-PD-L1 immunotherapy with the SRA737+LDG regimen may represent the optimal implementation of these agents, leading to a dramatic anti-tumour activity and provide a strong rationale for combining these agents with the SRA737+LDG regimen to enhance clinical response rates.\n \nDr Tim Mitchell, CEO of Sareum Holdings plc, said: \"The model data presented are very exciting with all examples treated with SRA737, LDG and anti-PD-L1 showing tumour regression and 80% having a complete response, with no detectable cancer. This provides a clear early demonstration of the potential of SRA737+LDG to enhance anti-PD-L1 immunotherapy in small cell lung cancer, a cancer type where such immunotherapies have shown limited benefit. We will follow the progress of studies using this novel combination approach with great interest.\"\n \nLung cancer is by far the leading cause of cancer death among both men and women and about 10-15% are SCLC. Each year, more people die o...